Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outc

[Guest guest]

Antivir Ther. 2008;13(2):307-18.

Virological pattern in plasma, peripheral blood mononuclear cells and liver

tissue and clinical outcome in chronic hepatitis B and C virus coinfection.

Coppola N, Pisapia R, Tonziello G, i S, Imparato M, Piai G, Stanzione M,

Sagnelli C, Filippini P, Piccinino F, Sagnelli E.

Department of Public Medicine, Second University of Naples, Italy.

BackgrounD: We aim to evaluate in chronic hepatitis B virus-hepatitis C virus

(HBV-HCV) coinfection the interplay of these viruses in liver tissue, peripheral

blood mononuclear cells (PBMC), and plasma and to analyze the effect on disease

course and response to treatment. METHODS: We enrolled 19 patients with chronic

HBV-HCV coinfection, 20 with chronic HCV and 20 with chronic HBV infection at

their first liver biopsy, all were naive for antiviral therapy. The patients'

plasma, PBMC and liver biopsy samples were tested for HBV DNA and/or HCV RNA by

real-time PCR, according to the presence/absence of hepatitis B surface antigen

and antibodies against HCV in the serum. RESULTS: Contemporary presence of HBV

DNA and HCV RNA was rare in plasma (5.3% of cases) and PBMC (10.6%), but

frequent in liver tissue (52.6%). Of 10 cases circulating only HCV RNA and

treated with pegylated interferon (PEG-IFN) plus ribavirin for 12 months, two

showed a sustained response, and eight cleared HCV RNA but became

HBV-DNA-positive in plasma; these eight had detectable HBV DNA in liver at

baseline. One patient, who was plasma HBV-DNA-positive/HCV-RNA-negative at

baseline, showed a sustained response after 18 months of PEG-IFN treatment;

another, who was plasma HBV-DNA/HCV-RNA-positive at baseline, cleared only HCV

RNA during 12 months of PEG-IFN plus ribavirin treatment. Seven cases remained

untreated. CONCLUSION: Despite a reciprocal inhibition in plasma, HBV and HCV

frequently coexist in liver tissue, a condition to be taken into consideration

when deciding therapy.

Publication Types:

Research Support, Non-U.S. Gov't

PMID: 18505182 [PubMed - in process]

_________________________________________________________________

Instantly invite friends from Facebook and other social networks to join you on

Windows Live™ Messenger.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_InviteFriends

[Guest guest]

Antivir Ther. 2008;13(2):307-18.

Virological pattern in plasma, peripheral blood mononuclear cells and liver

tissue and clinical outcome in chronic hepatitis B and C virus coinfection.

Coppola N, Pisapia R, Tonziello G, i S, Imparato M, Piai G, Stanzione M,

Sagnelli C, Filippini P, Piccinino F, Sagnelli E.

Department of Public Medicine, Second University of Naples, Italy.

BackgrounD: We aim to evaluate in chronic hepatitis B virus-hepatitis C virus

(HBV-HCV) coinfection the interplay of these viruses in liver tissue, peripheral

blood mononuclear cells (PBMC), and plasma and to analyze the effect on disease

course and response to treatment. METHODS: We enrolled 19 patients with chronic

HBV-HCV coinfection, 20 with chronic HCV and 20 with chronic HBV infection at

their first liver biopsy, all were naive for antiviral therapy. The patients'

plasma, PBMC and liver biopsy samples were tested for HBV DNA and/or HCV RNA by

real-time PCR, according to the presence/absence of hepatitis B surface antigen

and antibodies against HCV in the serum. RESULTS: Contemporary presence of HBV

DNA and HCV RNA was rare in plasma (5.3% of cases) and PBMC (10.6%), but

frequent in liver tissue (52.6%). Of 10 cases circulating only HCV RNA and

treated with pegylated interferon (PEG-IFN) plus ribavirin for 12 months, two

showed a sustained response, and eight cleared HCV RNA but became

HBV-DNA-positive in plasma; these eight had detectable HBV DNA in liver at

baseline. One patient, who was plasma HBV-DNA-positive/HCV-RNA-negative at

baseline, showed a sustained response after 18 months of PEG-IFN treatment;

another, who was plasma HBV-DNA/HCV-RNA-positive at baseline, cleared only HCV

RNA during 12 months of PEG-IFN plus ribavirin treatment. Seven cases remained

untreated. CONCLUSION: Despite a reciprocal inhibition in plasma, HBV and HCV

frequently coexist in liver tissue, a condition to be taken into consideration

when deciding therapy.

Publication Types:

Research Support, Non-U.S. Gov't

PMID: 18505182 [PubMed - in process]

_________________________________________________________________

Instantly invite friends from Facebook and other social networks to join you on

Windows Live™ Messenger.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_InviteFriends